Crohn's Disease Clinical Trials in Chapel Hill, North Carolina

5 studies are recruiting for crohn's disease in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   University of North Carolina Medical Center ( Site 5034), Chapel Hill, North Carolina

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

2. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill, North Carolina

   Locations

   301 in total

   Run by

   Sanofi

   See if you can join NCT07184931 on ClinicalTrials.gov

3. Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effec…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Univ NC Chapel Hill /ID# 262198, Chapel Hill, North Carolina

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT06332534 on ClinicalTrials.gov

4. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill, North Carolina

   Locations

   35 in total

   Run by

   Sanofi

   See if you can join NCT07184944 on ClinicalTrials.gov

5. A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

   This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Investigational Site Number: 8400003, Chapel Hill, North Carolina

   Locations

   66 in total

   Run by

   Sanofi

   See if you can join NCT06958536 on ClinicalTrials.gov